Comparing Coeptis Therapeutics (COEP) and Its Peers

Coeptis Therapeutics (NASDAQ:COEPGet Free Report) is one of 474 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Coeptis Therapeutics to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, institutional ownership, dividends and profitability.


This table compares Coeptis Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coeptis Therapeutics N/A -794.75% -322.86%
Coeptis Therapeutics Competitors -9,800.80% -120.48% -25.38%

Risk & Volatility

Coeptis Therapeutics has a beta of -0.89, meaning that its stock price is 189% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics’ rivals have a beta of 1.14, meaning that their average stock price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Coeptis Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coeptis Therapeutics 0 0 1 0 3.00
Coeptis Therapeutics Competitors 727 2536 6485 76 2.60

Coeptis Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 806.34%. As a group, “Biotechnology” companies have a potential upside of 128.30%. Given Coeptis Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Coeptis Therapeutics is more favorable than its rivals.

Institutional and Insider Ownership

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 31.3% of shares of all “Biotechnology” companies are owned by institutional investors. 21.5% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 21.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Coeptis Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Coeptis Therapeutics $80,000.00 -$21.27 million -0.39
Coeptis Therapeutics Competitors $196.85 million -$8.79 million -73.22

Coeptis Therapeutics’ rivals have higher revenue and earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


Coeptis Therapeutics rivals beat Coeptis Therapeutics on 7 of the 13 factors compared.

Coeptis Therapeutics Company Profile

(Get Free Report)

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.

Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with's FREE daily email newsletter.